TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04379596
Drug: Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU: administered as an IV infusion
Study: NCT04379596
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: administered orally
Study: NCT01490788
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNX-102 2.4 mg - 1 gelcap once under fasting conditions.
Study: NCT01490788
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions
Study: NCT03690323
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.
Study: NCT03958981
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the control group will be given a sunflower oil as a placebo with a similar texture to castor oil
Study: NCT01955603
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered corresponding to NNC0215-0384 treatment
Study: NCT01565382
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection, 370MBq (10mCi), single dose (intervention for Study A05 participants, source of scans for this study)
Study: NCT01274936
Drug: Qishe Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill, 3.75 g, twice per day, four weeks
Study: NCT01820936
Drug: Sequence 1: PCI-32765
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B
Study: NCT01820936
Drug: Sequence 2: PCI-32765
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C
Study: NCT01820936
Drug: Sequence 4: PCI-32765
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A
Study: NCT01820936
Drug: Sequence 5: PCI-32765
Approvals — FDA: no, EMA: no, PMDA: no
Description: After completion of the 4-way crossover, an additional separate cohort of 8 subjects were enrolled. These subjects participated in 1 treatment period to document safety and PK
Study: NCT01132612
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIN457A 150 mg powder for solution
Study: NCT01132612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to AIN457A 150 mg powder for solution
Study: NCT02524197
Drug: CR845 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will dose orally twice a day with CR845 5 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
Study: NCT03462069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT03462069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT02427620
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02427620
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02427620
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02427620
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02772640
Drug: Rosuvastatin and Ezetimibe morning or evening administration
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timing of the drug administration:~morning -\> evening evening -\> morning
Study: NCT06308861
Drug: Single administration Amg dose Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Amg tablet single administration
Study: NCT06308861
Drug: Single administration Cmg dose Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Cmg tablet single administration
Study: NCT06308861
Drug: Single administration Dmg dose Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Dmg tablet single administration
Study: NCT06308861
Drug: Single administration Emg dose Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Emg tablet single administration
Study: NCT06308861
Drug: Single administration Amg dose Group-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Placebo Amg tablet, single administration
Study: NCT06308861
Drug: Single administration Bmg dose Group-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Placebo Bmg tablet, single administration
Study: NCT06308861
Drug: Single administration Cmg dose Group-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Placebo Cmg tablet, single administration
Study: NCT06308861
Drug: Single administration Dmg dose Group-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Placebo Dmg tablet, single administration
Study: NCT06308861
Drug: Single administration Emg dose Group-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Placebo Emg tablet, single administration
Study: NCT06308861
Drug: Multiple administration Bmg dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Bmg 1 tablet, once a day for 3 days, multiple administration
Study: NCT00190515
Drug: 5FU+l-leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU+l-leucovorin
Study: NCT00190515
Drug: UFT+Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT+Leucovorin
Study: NCT06308861
Drug: Multiple administration Cmg dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Cmg 1 tablet, once a day for 3 days, multiple administration
Study: NCT06308861
Drug: Multiple administration Dmg dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Dmg 1 tablet, once a day for 3 days, multiple administration
Study: NCT06308861
Drug: Multiple administration Emg dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Emg 1 tablet, once a day for 3 days, multiple administration
Study: NCT06308861
Drug: Multiple administration Amg dose group - Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Placebo Amg 1 tablet, once a day for 3 days, multiple administration
Study: NCT06308861
Drug: Multiple administration Bmg dose group - Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Placebo Bmg 1 tablet, once a day for 3 days, multiple administration
Study: NCT06308861
Drug: Multiple administration Cmg dose group - Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Placebo Cmg 1 tablet, once a day for 3 days, multiple administration
Study: NCT06308861
Drug: Multiple administration Emg dose group - Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Placebo Emg 1 tablet, once a day for 3 days, multiple administration
Study: NCT02289352
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00354081
Drug: folic acid, vitamin B12 (cyanocobalamin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day
Study: NCT00354081
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, in a capsule, taken orally once a day
Study: NCT05132270
Drug: hydroxyurea and thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
Study: NCT01858584
Drug: Gastrotuss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~* Infants weighing \<5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~* Infants weighing\> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day
Study: NCT00201331
Drug: leucovorin+5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02711345
Drug: LTT462
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERK Inhibitor
Study: NCT01863810
Drug: KW21052
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.
Study: NCT01863810
Drug: Placebo of KW21052
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral,once a day, for 8 weeks
Study: NCT01863810
Drug: Placebo of Lyrica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, twice a day, for 8 weeks.
Study: NCT03429439
Drug: Antiviral Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants continue present antiviral therapy over 12 months.
Study: NCT03198637
Drug: clinical assessment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04296383
Drug: Azithromycin plus Xiyanping injection
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d;Xiyanping injection intravenously, 0.4mL / (kg.d) daily, Qd
Study: NCT04296383
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d
Study: NCT00752544
Drug: TMC435350
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03606395
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo liquid solution to mimic NV-5138
Study: NCT02571036
Drug: DCC-2618
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg formulated tablets
Study: NCT02571036
Drug: DCC-2618
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg and 50 mg formulated tablets
Study: NCT00908011
Drug: Rosuvastatin (standard care)
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Increased dose of rosuvastatin to 20mg/day
Study: NCT01724476
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00628394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg 2po qam
Study: NCT04023994
Drug: RO7126209
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.
Study: NCT04023994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered a single intravenous dose of matching placebo.
Study: NCT03899337
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750mg/m\^2, IV bolus
Study: NCT03899337
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m\^2, IV bolus
Study: NCT03899337
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg/m\^2, PO, OD
Study: NCT02468661
Drug: INC280 single agent
Normalized name: MISCELLANEOUS AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03015519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be delivered from a prefilled dual chamber glass cartridge DCC. The pen injector system will deliver 0.5 mL matching placebo as a single subcutaneous injection once a week.
Study: NCT03137082
Drug: Placebo (for guanfacine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic guanfacine tablets
Study: NCT00206466
Drug: Adriamycin/cytoxan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
Study: NCT01281696
Drug: Intrathecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Additional intrathecal methotrexate only given in patients with leptomeningeal metastasis
Study: NCT00000574
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03953781
Drug: Effect of valporate on Reproductive Functions in Newly Diagnosed Epileptic Males
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03187756
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Shortened duration immunosuppression following nonmyeloablative peripheral blood stem cell transplant with high dose post transplantation cyclophosphamide in malignancies to engraft.
Study: NCT02301988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
Study: NCT01532973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo tablets were administered orally.
Study: NCT04541082
Drug: ONC206
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC206 is a member of the imipridone class of anti-cancer small molecules that share a unique tri-heterocyclic core chemical structure and target G protein-coupled receptors.
Study: NCT01473758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, od, oral administration in the morning after breakfast
Study: NCT02199652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02622074
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m\^2 administered Q3W as an IV infusion.
Study: NCT04109456
Drug: IN10018
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg or 50mg, orally once daily continuously;
Study: NCT04048200
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anesthesia will be induced by fentanyl, propofol, and rocuronium with maintenance of anesthesia using sevoflurane.
Study: NCT00103103
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00103103
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01223196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo for comparison to Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
Study: NCT01238822
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02529800
Drug: HIP1402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin HCl 0.4mg
Study: NCT02529800
Drug: HGP0412
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin HCl 0.2mg
Study: NCT00883584
Drug: IMD-1041
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
Study: NCT00883584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
Study: NCT04570267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution of CSL324 formulation buffer for injection
Study: NCT04417543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
Study: NCT01517334
Drug: Minocycline HCl Microspheres
Normalized name: minocycline HCl microspheres
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01871857
Drug: Hypertonic saline and epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01871857
Drug: Normal saline and epinephrine
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00354510
Drug: GW842470X cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00274755
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01090128
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 every 3 weeks
Study: NCT01090128
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2 given every 3 weeks
Study: NCT01511900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort
Study: NCT01452009
Drug: TRAVATAN®
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAVATAN® administered one drop once daily
Study: NCT01218737
Drug: isolated 0.3% gatifloxacin and 1.0% prednisolone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the 0.3% gatifloxacin eye drops and another with 1.0% prednisolone acetate eye drops. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15.
Study: NCT00492388
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01361607
Drug: Placebo (GA-0034)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00403403
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve \[AUC\]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.
Study: NCT00403403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
Study: NCT04405193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT00390156
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Current dose 50 mg
Study: NCT03945357
Drug: Gemcitabine/ clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of saline solution rinse vs antibiotic rinse
Study: NCT01648023
Drug: Gem-Cis or Gem-Carbo
Normalized name: Carbo animalis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00618423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
Study: NCT03616496
Drug: Neuraceq PET/CT imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/CT with Neuraceq injection, blood and urine sampling for protein electrophoresis, bone scintigraphy for the three arm (if the exams are present in the patient's medical record and are less than 3 months old, they do not need to be repeated
Study: NCT02423603
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
Study: NCT03945357
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of saline solution rinse vs antibiotic rinse
Study: NCT02423603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
Study: NCT01407679
Drug: Alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
Study: NCT00171678
Drug: Diclofenac Topical Sodium Gel 1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02637128
Drug: artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight
Study: NCT02067715
Drug: Tooth bleaching
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The bleaching agent will be used in a single-application of 45 minutes.